Navegando por Autor "SOUZA, Ana Maria Almeida"

Agora exibindo 1 - 2 de 2

Acesso aberto (Open Access)
Autoanticorpos contra antígenos celulares e sua correlação com o genótipo viral em pacientes com infecção pelo vírus da Hepatite C (HCV)
(Universidade Federal do Pará, 2011) SOUZA, Ana Maria Almeida; QUARESMA, Juarez Antônio Simões; http://lattes.cnpq.br/3350166863853054
Inflammation of the liver caused by hepatotropic viruses affect millions of people and represents a significant public health problem worldwide. There are interactions between hepatotropic viruses and the host immune system that can influence the pathogenesis of liver injury. The objective of this study was to investigate the frequency of autoantibodies in patients with hepatitis C virus, and its correlation with the genotypes found. We studied 51 patients diagnosed by PCR of infection with hepatitis C and a group of 100 blood donors with all serological tests for infectious diseases negative. The 51 patients with virus C had an average age of 43 years, + / - 11.3, in the pre-treatment, 34 (66.7%) were male and 17 (33.3%) were female. Of these 13 (25.5%) were ANA positive, 45 (88.2%) were with genotype 1 and 11.8% with genotype 3. Patients who presented with antibodies had no detectable levels of AST, ALT, AST / ALT, γ-GT and alkaline phosphatase significantly different from those with negative antibody titers. Thus, we conclude that the antibodies present in the study sample are independent of disease progression and patient prognosis, though seems to be linked with genotype 1.
Acesso aberto (Open Access)
Study of enzyme replacement therapy for Gaucher Disease: comparative analysis of clinical and laboratory parameters at diagnosis and after two, five and ten years of treatment
(Universidade Federal do Pará, 2014-10) SOUZA, Ana Maria Almeida; MUNIZ, Thiago Pimentel; BRITO, Rafael Maciel
Objective: to evaluate the impact of enzyme replacement therapy for Gaucher Disease on clinical and laboratory parameters after two, five and ten years of treatment. Methods: data were collected from patient records and analyzed using BioEstat software (version 5.0). Student's t-test, Analysis of Variance (ANOVA), Wilcoxon test and Kruskal–Wallis test were used for statistical analysis. Hepatomegaly and splenomegaly were analyzed using the Kappa test. Results: there was a significant increase in hemoglobin levels (p-value <0.01) and platelet counts (p-value = 0.01) within two years of therapy. At the same time, the frequencies of splenomegaly (p-value <0.01) and hepatomegaly (p-value <0.05) reduced. These results were similar at five and ten years of enzyme replacement therapy. Conclusions: there are substantial and quick (within two years) laboratory and clinical responses to enzyme replacement therapy. These improvements continue as long as enzyme replacement therapy is administered every two weeks, as recommended by the literature.